Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | CDC25A | P30304 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | GMNN | O75496 | 3/20 | 0.35 |
| ▸ | BLM | P54132 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605941 | 0.85 | FABP3 (0.40) | FABP3LMNAAKT1ESR1ADORA3 | |
| SCHEMBL2602823 | 0.82 | FABP3 (0.40) | FABP3LMNAAKT1ESR1ADORA3 | |
| SCHEMBL2602822 | 0.81 | FABP3 (0.48) | FABP3LMNAMAPK1MEN1GMNN | |
| SCHEMBL13619257 | 0.75 | FABP3 (0.40) | FABP3LMNAAKT1ESR1ADORA3 | |
| SCHEMBL14447854 | 0.74 | LMNA (0.47) | FABP3LMNAAKT1ESR1ADORA3 | |
| SCHEMBL11120116 | 0.73 | FABP3 (0.43) | FABP3LMNAAKT1ESR1ADORA3 | |
| SCHEMBL5959370 | 0.73 | FABP3 (0.48) | FABP3LMNAAKT1ESR1ADORA3 | |
| SCHEMBL12235485 | 0.72 | MAPK1 (0.59) | FABP3LMNAAKT1MAPK1MEN1 | |
| SCHEMBL29059526 | 0.72 | MAPK1 (0.59) | FABP3LMNAAKT1MAPK1MEN1 | |
| SCHEMBL13480679 | 0.72 | FABP3 (0.48) | FABP3LMNAAKT1ESR1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158611-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2012-04-17 | — | — | US | disclosed |
| US-20110097350-A1 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | VASCULAR BIOGENICS LTD. (IL) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097350-A1 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | PHOSPHO1, GPX4, SGMS1 | FABP3 251/4885LMNA 1687/4885AKT1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.